Recent News

• 04.23.2025 - Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
• 04.23.2025 - Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
• 03.29.2025 - Advance-HTN 2025 Presentation: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
• 03.29.2025 - Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
• 03.25.2025 - Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
• 03.18.2025 - Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
• 03.17.2025 - Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

Recent Filings

• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.14.2025 - 144 Report of proposed sale of securities
• 04.11.2025 - 144 Report of proposed sale of securities
• 04.11.2025 - 144 Report of proposed sale of securities
• 04.09.2025 - ARS Annual Report to Security Holders
• 04.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.09.2025 - DEF 14A Other definitive proxy statements
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities